POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial hopes to tame rare blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called PRT12396 in about 100 people with polycythemia vera or myelofibrosis, which are types of blood cancers. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific gene m…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 17, 2026 03:43 UTC
-
New hope for myelofibrosis patients who fail current therapies
Disease control Recruiting nowThis early-stage study tests an experimental pill, AJ1-11095, in people with a bone marrow cancer called myelofibrosis. Participants must have already tried a standard JAK2 inhibitor without success. The main goals are to check the drug's safety and find the best dose for future …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug aims to free blood cancer patients from transfusions
Disease control Recruiting nowThis study is testing an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can help patients produce enough red blood cells so they no longer need regular blood transfus…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Blood cancer drug bomedemstat tested for Long-Term safety in 400 patients
Disease control Recruiting nowThis study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who have already been taking the drug bomedemstat and are doing well on it. The goal is to collect more information on the drug's long-term safety and how well it continues to wo…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New study aims to map Real-World care for rare bone marrow disease
Knowledge-focused Recruiting nowThis study is a registry that will follow about 200 people in Germany who have myelofibrosis (a rare bone marrow disorder) and anemia. It does not test a new treatment but instead collects information on which therapies patients receive, how their blood counts and spleen size res…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated May 17, 2026 03:39 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC